Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2017

01-02-2017 | Research Article

Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit

Authors: P. Joret-Descout, S. Dauger, M. Bellaiche, O. Bourdon, S. Prot-Labarthe

Published in: International Journal of Clinical Pharmacy | Issue 1/2017

Login to get access

Abstract

Background Stress ulcer prophylaxis (SUP) is recommended in some situations to prevent upper gastrointestinal bleeding and is a component of standard care for patients admitted to the intensive care unit (ICU). Proton pump inhibitors (PPIs), already among the most widely prescribed drug classes, are being increasingly used. Objective To describe PPI prescribing patterns and their changes after the dissemination of guidelines. Setting Paediatric ICU (PICU), Robert-Debré Teaching Hospital, Paris, France, which admits about 800 patients annually, from full-term neonates to 18-year-olds. Method Prospective observational study with two 6-week observation periods (July–August and September–October, 2013), before and after dissemination in the PICU of PPI prescribing guidelines. Main outcome measure Changes in PPI prescribing patterns (prevalence, dosage, and indication) after the guidelines. Results The number of patients admitted to the PICU was 77 (mean age 4.6 years [range 1 day–18 years]) before and 70 (mean age 3.8 years [range 1 day–17 years]) after the guidelines. During both periods, SUP was the most common reason for PPI prescribing. The proportion of patients prescribed PPIs dropped significantly, from 51% before the guidelines to 30% after the guidelines (p < 0.001). Mean daily dosage also decreased significantly, from 1.5 mg/kg/(range 0.5–4.4) to 1.1 mg/kg (range 0.7–1.8) (p < 0.002). None of the patients experienced upper gastrointestinal bleeding during either period. Conclusion Off-label PPI prescribing for SUP was common in our PICU. The introduction of guidelines was associated with a significant decrease in PPI use and dosage. This study confirms that guidelines can change PPI prescribings patterns in paediatric practice.
Literature
2.
go back to reference Smith CH, Israel DM, Schreiber R, Goldman RD. Proton pump inhibitors for irritable infants. Can Fam Physician. 2013;59:153–6.PubMedPubMedCentral Smith CH, Israel DM, Schreiber R, Goldman RD. Proton pump inhibitors for irritable infants. Can Fam Physician. 2013;59:153–6.PubMedPubMedCentral
3.
go back to reference Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy. 2013;33:956–71.CrossRefPubMed Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy. 2013;33:956–71.CrossRefPubMed
4.
go back to reference Tafuri G, Trotta F, Leufkens HGM, Martini N, Sagliocca L, Traversa G. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol. 2009;65:209–16.CrossRefPubMed Tafuri G, Trotta F, Leufkens HGM, Martini N, Sagliocca L, Traversa G. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol. 2009;65:209–16.CrossRefPubMed
5.
go back to reference ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;15(56):347–79. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;15(56):347–79.
6.
go back to reference Krag M, Perner A, Wetterslev J, Møller MH. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand. 2013;57:835–47.CrossRefPubMed Krag M, Perner A, Wetterslev J, Møller MH. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand. 2013;57:835–47.CrossRefPubMed
7.
go back to reference Pimentel M, Roberts DE, Bernstein CN, Hoppensack M, Duerksen DR. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol. 2000;95:2801–6.CrossRefPubMed Pimentel M, Roberts DE, Bernstein CN, Hoppensack M, Duerksen DR. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol. 2000;95:2801–6.CrossRefPubMed
8.
go back to reference Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5:368–75.CrossRefPubMedPubMedCentral Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5:368–75.CrossRefPubMedPubMedCentral
9.
go back to reference Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693–705.CrossRefPubMed Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693–705.CrossRefPubMed
10.
go back to reference Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310–9.CrossRefPubMedPubMedCentral Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310–9.CrossRefPubMedPubMedCentral
11.
go back to reference Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–90.CrossRefPubMed Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–90.CrossRefPubMed
12.
go back to reference MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174:564–74.CrossRefPubMed MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174:564–74.CrossRefPubMed
13.
go back to reference Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38:2222–8.CrossRefPubMed Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38:2222–8.CrossRefPubMed
14.
go back to reference Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5:219–32.CrossRef Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5:219–32.CrossRef
15.
go back to reference Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16:122–9.PubMed Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16:122–9.PubMed
16.
go back to reference Lightdale JR, Gremse DA. Section on gastroenterology, hepatology and nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131:1684–95.CrossRef Lightdale JR, Gremse DA. Section on gastroenterology, hepatology and nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131:1684–95.CrossRef
18.
go back to reference Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1–11 months. J Pediatr Gastroenterol Nutr. 2012;55:14–20.CrossRefPubMed Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1–11 months. J Pediatr Gastroenterol Nutr. 2012;55:14–20.CrossRefPubMed
19.
go back to reference Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498–547.CrossRefPubMed Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498–547.CrossRefPubMed
20.
go back to reference Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25:214–20.CrossRefPubMed Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25:214–20.CrossRefPubMed
21.
go back to reference Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med. 1988;16:1110–6.CrossRefPubMed Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med. 1988;16:1110–6.CrossRefPubMed
22.
go back to reference Slater A, Shann F, Pearson G. Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med. 2003;29:278–85.CrossRefPubMed Slater A, Shann F, Pearson G. Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med. 2003;29:278–85.CrossRefPubMed
23.
go back to reference Leteurtre S, Duhamel A, Grandbastien B, Lacroix J, Leclerc F. Paediatric logistic organ dysfunction (PELOD) score. Lancet. 2006;367:897 (author reply 900–2).CrossRefPubMed Leteurtre S, Duhamel A, Grandbastien B, Lacroix J, Leclerc F. Paediatric logistic organ dysfunction (PELOD) score. Lancet. 2006;367:897 (author reply 900–2).CrossRefPubMed
24.
go back to reference Carnovale C, Conti V, Perrone V, Antoniazzi S, Pozzi M, Merlino L, et al. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172:1679–85.CrossRefPubMed Carnovale C, Conti V, Perrone V, Antoniazzi S, Pozzi M, Merlino L, et al. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172:1679–85.CrossRefPubMed
25.
go back to reference Lenz K, Buder R, Firlinger F, Lohr G, Voglmayr M. Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress. Wien Klin Wochenschr. 2015;127:51–6.CrossRefPubMed Lenz K, Buder R, Firlinger F, Lohr G, Voglmayr M. Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress. Wien Klin Wochenschr. 2015;127:51–6.CrossRefPubMed
26.
go back to reference Haroon M, Yasin F, Gardezi S, Adeeb F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4:1–6.CrossRef Haroon M, Yasin F, Gardezi S, Adeeb F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4:1–6.CrossRef
27.
go back to reference Barletta JF, Kanji S, MacLaren R, Lat I, Erstad BL. American-Canadian consortium for Intensive care Drug utilization (ACID) Investigators. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. J Crit Care. 2014;29:955–60.CrossRefPubMed Barletta JF, Kanji S, MacLaren R, Lat I, Erstad BL. American-Canadian consortium for Intensive care Drug utilization (ACID) Investigators. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. J Crit Care. 2014;29:955–60.CrossRefPubMed
28.
go back to reference Gautam A, Ganu SS, Tegg OJ, Andresen DN, Wilkins BH, Schell DN. Ventilator-associated pneumonia in a tertiary paediatric intensive care unit: a 1-year prospective observational study. Crit Care Resusc. 2012;14:283–9.PubMed Gautam A, Ganu SS, Tegg OJ, Andresen DN, Wilkins BH, Schell DN. Ventilator-associated pneumonia in a tertiary paediatric intensive care unit: a 1-year prospective observational study. Crit Care Resusc. 2012;14:283–9.PubMed
29.
go back to reference Atkins R, Smith L. Impact of pharmacy intervention on the use of proton-pump inhibitors in the hospital setting. Consult Pharm. 2013;28:786–92.CrossRefPubMed Atkins R, Smith L. Impact of pharmacy intervention on the use of proton-pump inhibitors in the hospital setting. Consult Pharm. 2013;28:786–92.CrossRefPubMed
30.
go back to reference Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA Jr. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106:270–3.CrossRefPubMed Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA Jr. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106:270–3.CrossRefPubMed
31.
go back to reference Machado-Alba JE, Castrillón-Spitia JD, Londoño-Builes MJ, Fernández-Cardona A, Campo-Betancourth CF, Ochoa-Orozco SA, et al. An economic analysis of inadequate prescription of antiulcer medications for in-hospital patients at a third level institution in Colombia. Rev Esp Enferm Dig. 2014;106:77–85.CrossRefPubMed Machado-Alba JE, Castrillón-Spitia JD, Londoño-Builes MJ, Fernández-Cardona A, Campo-Betancourth CF, Ochoa-Orozco SA, et al. An economic analysis of inadequate prescription of antiulcer medications for in-hospital patients at a third level institution in Colombia. Rev Esp Enferm Dig. 2014;106:77–85.CrossRefPubMed
32.
go back to reference MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Crit Care Med. 2014;42:809–15.CrossRefPubMed MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Crit Care Med. 2014;42:809–15.CrossRefPubMed
33.
go back to reference Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics. 2014;32:5–13.CrossRefPubMed Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics. 2014;32:5–13.CrossRefPubMed
Metadata
Title
Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit
Authors
P. Joret-Descout
S. Dauger
M. Bellaiche
O. Bourdon
S. Prot-Labarthe
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2017
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0420-4

Other articles of this Issue 1/2017

International Journal of Clinical Pharmacy 1/2017 Go to the issue